StemCells - die neue Generation von Biotech ??? - 500 Beiträge pro Seite

[dochmax]

Viel Phantasie - hohe Verluste! Wer weiß mehr?
Es geht um die unendliche Teilungsfähigkeit embryonaler Zellen. An sich schon etwas Gutes - aber auch übertragbar auf die Aktien des Unternehmens?

[For4]

In der aktuellen Ausgabe von Finanzen steht ein großer Artikel dazu!

[schlitzauge26]

klaere mich mal einer ueber die aktie auf!

[Michael16]

StemCells, Inc. (formerly CytoTherapeutics) hopes a small focus will mean big business. The company
discovers, develops, and markets cell-based therapies to treat diseases of the central nervous system, liver, and
pancreas. The company is developing encapsulated-cell therapies that would be implanted into the body, and is
researching stem cell therapies to repair or repopulate neural or other tissue that has been damaged or lost as a
result of disease or injury. StemCells` human nerve stem cells are being tested as to whether they can become
mature brain cells. The company sold its encapsulated cell technology to Neurotech S.A.
525 Del Rey Ave., Ste. C
Sunnyvale, CA 94086
408-731-8670

CEO:
George Dunbar
Employees:
21
Fiscal Year End:
December
1999 Sales ($ Mil.):
$5.0
1-Yr Sales Change:
(43.2%)
Net Income ($ Mil.):
($15.7)
Ticker Symbol:
STEM
Exchange:
Nasdaq

[DOXA DRAMA]

last 4,50$ +16,12% in USA 18:21Uhr
der kurs aber wird in deutschland gemacht
das ist sehr positiv
kursziel morgen 5,60-6 euro

[Mr. Salami]

Der Leader in der Stammzellenforschung ist Geron (GERN).

Haben bereits ein Agreement mit Celera.

[DOXA DRAMA]

Es sieht noch besser in USA aus
BID 4,625$

[DOXA DRAMA]

last 4,688$
16:06Uhr

[DOXA DRAMA]

LAST 4,969$
16:28

[DOXA DRAMA]

last 5,25$ 17:47Uhr
+16,66%

[Michael16]

Gut das Mann von vor zwei Tagen Investiert hat!!!!!!!

[Mattek]

Vergesst KGV, nehmt fantasie, nehmt STEM

TELEBÖRSE + Nachfolgendes = + 45 % in vier Tagen (ende offen)


StemCells, Inc. Announces Private Placement

SUNNYVALE, Calif., Aug 7, 2000 (BW HealthWire) -- StemCells, Inc. (Nasdaq:
STEM) announced today that it has completed a $4 million common stock financing
transaction with a prominent investment fund with more than a billion dollars in
assets under management. StemCells received $3 million of the purchase price at
the closing and will receive the remaining $1 million upon effectiveness of a
registration statement covering the shares owned by the Fund.

The Fund purchased the Company`s common stock at $4.33 per share. The Fund will
be entitled to receive additional shares of common stock on eight dates
beginning six months from the closing and every three months thereafter. The
number of additional shares to which the Fund will be entitled on each date will
be based on the number of shares of the common stock the Fund continues to hold
on each date and the market price of the Company`s common stock over a period
prior to each date. The Company will have the right, under certain
circumstances, to cap the number of additional shares by purchasing part of the
entitlement from the Fund. The Fund also received a warrant to purchase up to
101,587 shares of common stock at $4.725 per share. This warrant is callable by
StemCells at $8.6625 per underlying share. In addition, the Fund has the option
for twelve months to purchase up to $3 million of additional common stock.

"We are pleased with this financing, which we believe will give us adequate
short term resources as we improve the funding of our research programs," stated
George Dunbar, Acting President and CEO of StemCells. "We are also pleased about
the very successful IPO of Modex Therapeutics Ltd, of which we own approximately
126,000 shares." StemCells, Inc. (then known as CytoTherapeutics, Inc.) was one
of the founders of Modex, a Swiss biotherapeutics company established in 1996 to
pursue encapsulated cell technologies related to former programs of the Company.
Modex`s share price has risen over 40% to date from its June 23 Initial Public
Offering on the Swiss Neue Markt. The performance of the stock since its IPO
does not predict its future value.

StemCells, Inc., is a biotechnology company focused on the discovery,
development and commercialization of stem cell-based therapies to treat diseases
of the central nervous system, liver, and pancreas. The Company`s stem cell
programs seek to repair or repopulate neural or other tissue that has been
damaged or lost as a result of disease or injury.

Apart from statements of historical facts, the text of this press release
constitutes forward looking statements regarding, among other things, the future
business operations of StemCells, Inc., or of StemCells California, Inc., its
wholly-owned subsidiary (collectively, "the Company"). The Company`s actual
results may vary materially from those contemplated in the forward looking
statements due to risks and uncertainties to which the Company is subject,
including uncertainties regarding the Company`s ability to obtain the capital
resources needed to conduct the research, preclinical development and clinical
trials necessary for regulatory approvals; the fact that the Company`s stem cell
technology is at the pre-clinical stage and has not yet led to the development
of any proposed product; the uncertainty whether any products that may be
generated in the future in the Company`s stem cell programs will prove
clinically effective and not cause tumors or other side effects; the uncertainty
whether the Company will achieve revenues from product sales or become
profitable; and others that are described in Exhibit 99 to the Company`s Annual
Report on Form 10-K entitled "Cautionary Factors Relevant to Forward Looking
Statements."


CONTACT: StemCells, Inc.
George Dunbar, 408/731-8670
or
IR PR Strategies, LLC
Anette Breindl, 858/860-0266 (Media)

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.



KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL

[Lemming-Töter]

Die letzten Tagen waren ganz gut! Trotz Empfehlung in der "TELEBÖRSE" (100% Chance) ist der Wert auch weiterhin sehr volantil...!

Ein spekulatives Investment...!


...sollte man seinem Depot beimischen!

[tapello]

sach mal, arbeiten die nicht mit Zellen aus dem Hirn von Föten?

[PuetzM]

@tapello
Heute morgen war ein Bericht über den Einsatz von Stammzellen, der Forschung, und den zukünftigen Chancen auf VOX zu sehen.
z.B. hat man einem Schlaganfallpatient Stammzellen, in die, durch den Schlaganfall beschädigten Bereiche transplantiert und siehe da, er konnte einige seiner Glieder wieder, wenn auch nur teilweise, nutzen!
Stammzellen wurden in diesem Beispiel aus einer bestimmten Art von Tumor entnommen. Diese Tumoren treten wohl bei Männern in den Hoden
(Spermien) und bei Frauen in den Eierstöcken(Eizellen) auf.
War richtig interressant....

[Lanzelotte]

Kurse werden in Deutschland gemacht - die Aussage ist
ja der Brüller.

Ich sag euch mal wie das läuft. Da durch Finanzen und Telebörse
in Deutschland ein sehr hoher Aufschlag gezahlt wird, lohnt es
sich im Moment allemal die Dinger in US zu kaufen und hier in
Deutschland wieder zu verhökern. Da der Wert in US auch sehr
markteng ist (jedenfalls für deren Verhältnisse) ziehen dort die
Kurse natürlich nach. Ich selbst hab damit schon ganz gutes Geld
verdient.

Wenn der Wert hier in Deutschland wieder aus dem Focus ist, werden
sich 1. die Kurse wieder an die US Kurse angleichen und 2. die US Kurse
zusätzlich runtergehen. Also seit vorsichtig und bezahlt nicht zu hohe
Aufschläge.

Das heisst natürlich nicht, dass der Wert nicht mittel und langfristig
erheblich steigen kann. Aber die Kurssteigerungen müssen von America
ausgehen - nicht von Deutschland.

Gruss
Lanzelotte